Neurotoxicity of Cancer Chemotherapy

Edward J. Dropcho

doi:10.1055/s-2004-861536

Seminars in Neurology, Inhaltsverzeichnis

Semin Neurol 2004; 24(4): 419-426
DOI: 10.1055/s-2004-861536

Neurotoxicity of Cancer Chemotherapy

Edward J. Dropcho¹

¹Professor of Neurology, Department of Neurology, Indiana University Medical Center, and The Indianapolis Veterans Affairs Medical Center, Indianapolis, Indiana

Abstract

ABSTRACT

Neurological dysfunction is a common side effect of many chemotherapy drugs. For several agents neurotoxicity is common, severe, and can be dose-limiting. This is a review of the clinical features of chemotherapy-induced syndromes involving the central and peripheral nervous systems.

KEYWORDS

Chemotherapy adverse effects - polyneuropathy

Volltext

Referenzen

REFERENCES

1 Vassal G, Deroussent A, Hartmann O et al.. Dose-dependent neurotoxicity of high-dose busulfan in children: a clinical and pharmacological study. Cancer Res. 1990; 50 6203-6207
2 Wyllie A R, Bayliff C D, Kovacs M J. Myoclonus due to chlorambucil in two adults with lymphoma. Ann Pharmacother. 1997; 31 171-174
3 Dropcho E J, Rosenfeld S S, Vitek J, Guthrie B L, Morawetz R B. Phase II study of intracarotid or selective intracerebral infusion of cisplatin for treatment of recurrent anaplastic gliomas. J Neurooncol. 1998; 36 191-198
4 Baker W J, Royer G L, Weiss R B. Cytarabine and neurologic toxicity. J Clin Oncol. 1991; 9 679-693
5 Jaeckle K A, Batchelor T, O'Day S J et al.. An open label trial of sustained-release cytarabine (DepoCyt) for the intrathecal treatment of solid tumor neoplastic meningitis. J Neurooncol. 2002; 57 231-239
6 Leff R S, Thompson J M, Daly M B et al.. Acute neurologic dysfunction after high-dose etoposide therapy for malignant glioma. Cancer. 1988; 62 32-35
7 Pratt C B, Green A A, Horowitz M E et al.. Central nervous system toxicity following the treatment of pediatric patients with ifosfamide/mesna. J Clin Oncol. 1986; 4 1253-1261
8 Pratt C B, Goren M P, Meyer W H, Singh B, Dodge R K. Ifosfamide neurotoxicity is related to previous cisplatin treatment for pediatric solid tumors. J Clin Oncol. 1990; 8 1399-1401
9 DiMaggio J R, Brown R, Baile W F, Schapira D. Hallucinations and ifosfamide-induced neurotoxicity. Cancer. 1994; 73 1509-1514
10 Simonian N A, Gilliam F G, Chiappa K H. Ifosfamide causes a diazepam-sensitive encephalopathy. Neurology. 1993; 43 2700-2702
11 Pelgrims J, De Vos F, Van den Brande J et al.. Methylene blue in the treatment and prevention of ifosfamide-induced encephalopathy: report of 12 cases and a review of the literature. Br J Cancer. 2000; 82 291-294
12 Pavol M A, Meyers C A, Rexer J L et al.. Pattern of neurobehavioral deficits associated with interferon alfa therapy for leukemia. Neurology. 1995; 45 947-950
13 Valentine A D, Meyers C A, Kling M A, Richelson E, Hauser P. Mood and cognitive side effects of interferon-alpha therapy. Semin Oncol. 1998; 25(Suppl 1) 39-47
14 Hensley M L, Peterson B, Silver R T et al.. Risk factors for severe neuropsychiatric toxicity in patients receiving interferon alfa-2b and low-dose cytarabine for chronic myelogenous leukemia. J Clin Oncol. 2000; 18 1301-1308
15 Adams F, Fernandez F, Mavligit G. Interferon-induced organic mental disorders associated with unsuspected pre-existing neurologic abnormalities. J Neurooncol. 1988; 6 355-359
16 Meyers C A, Scheibel R S, Forman A D. Persistent neurotoxicity of systemically administered interferon-alpha. Neurology. 1991; 41 672-676
17 Musselman D L, Lawson D H, Gumnick J F et al.. Paroxetine for the prevention of depression induced by high-dose interferon alfa. N Engl J Med. 2001; 344 961-966
18 Denicoff K D, Rubinow D R, Papa M Z et al.. The neuropsychiatric effects of treatment with interleukin-2 and lymphokine-activated killer cells. Ann Intern Med. 1987; 107 293-300
19 Karp B I, Yang J C, Khorsand M, Wood R, Merigan T C. Multiple cerebral lesions complicating therapy with interleukin-2. Neurology. 1996; 47 417-424
20 Baz D V, Bofill J S, Noguiera J A. Irinotecan-induced dysarthria. J Natl Cancer Inst. 2001; 93 1419-1420
21 Sullivan K M, Storb R, Shulman H M et al.. Immediate and delayed neurotoxicity after mechlorethamine preparation for bone marrow transplantation. Ann Intern Med. 1982; 97 182-189
22 Nieto Y, Cagnoni P J, Bearman S I et al.. Acute encephalopathy: a new toxicity associated with high-dose Paclitaxel. Clin Cancer Res. 1999; 5 501-506
23 Perry J R, Warner E. Transient encephalopathy after paclitaxel (Taxol) infusion. Neurology. 1996; 46 1596-1599
24 Byrd R L, Rohrbaugh T M, Raney R B, Norris D G. Transient cortical blindness secondary to vincristine therapy in childhood malignancies. Cancer. 1981; 47 37-40
25 Hurwitz R L, Mahoney D H, Armstrong D L, Browder T M. Reversible encephalopathy and seizures as a result of conventional vincristine administration. Med Pediatr Oncol. 1988; 16 216-219
26 Rosenblum M K, Delattre J Y, Walker R W, Shapiro W R. Fatal necrotizing encephalopathy complicating treatment of malignant gliomas with intra-arterial BCNU and irradiation: a pathological study. J Neurooncol. 1989; 7 269-281
27 Hook C C, Kimmel D W, Kvols L K et al.. Multifocal inflammatory leukoencephalopathy with 5-fluorouracil and levamisole. Ann Neurol. 1992; 31 262-267
28 Savarese D M, Gordon J, Smith T W et al.. Cerebral demyelination syndrome in a patient treated with 5-fluorouracil and levamisole. Cancer. 1996; 77 387-394
29 Franco D A, Greenberg H S. 5-FU multifocal inflammatory leukoencephalopathy and dihydropyrimidine dehydrogenase deficiency. Neurology. 2001; 56 110-112
30 Takimoto C H, Lu Z H, Zhang R et al.. Severe neurotoxicity following 5-fluorouracil-based chemotherapy in a patient with dihydropyrimidine dehydrogenase deficiency. Clin Cancer Res. 1996; 2 477-481
31 Herrlinger U, Schabet M, Brugger W et al.. Primary central nervous system lymphoma: outcome and late adverse effects after combined modality treatment. Cancer. 2001; 91 130-135
32 Robain O, Dulac O, Dommergues J P et al.. Necrotising leukoencephalopathy complicating treatment of childhood leukaemia. J Neurol Neurosurg Psychiatry. 1984; 47 65-72
33 Miyatake S, Kikuchi H, Oda Y et al.. A case of treatment-related leukoencephalopathy: sequential MRI, CT and PET findings. J Neurooncol. 1992; 14 143-149
34 Rubinstein L J, Herman M M, Long T F, Wilbur J R. Disseminated necrotizing leukoencephalopathy: a complication of treated central nervous system leukemia and lymphoma. Cancer. 1975; 35 291-305
35 Chun H G, Leyland-Jones B R, Caryk S M, Hoth D F. Central nervous system toxicity of fludarabine phosphate. Cancer Treat Rep. 1986; 70 1225-1228
36 Cheson B D, Vena D A, Foss F M, Sorensen J M. Neurotoxicity of purine analogs. J Clin Oncol. 1994; 12 2216-2228
37 Cohen R B, Abdallah J M, Gray J R, Foss F. Reversible neurologic toxicity in patients treated with standard-dose fludarabine phosphate for mycosis fungoides and chronic lymphocytic leukemia. Ann Intern Med. 1993; 118 114-116
38 Feinberg W M, Swenson M R. Cerebrovascular complications of L-asparaginase therapy. Neurology. 1988; 38 127-133
39 Mitchell L G. A prospective cohort study determining the prevalence of thrombotic events in children with acute lymphoblastic leukemia and a central venous line who are treated with L-asparaginase. Cancer. 2003; 97 508-515
40 Icli F, Karaoguz H, Dincol D et al.. Severe vascular toxicity associated with cisplatin-based chemotherapy. Cancer. 1993; 72 587-593
41 El Amrani M, Henizlef O, Debroucker T et al.. Brain infarction following 5-fluorouracil and cisplatin therapy. Neurology. 1998; 51 899-901
42 Bernard J T, Ameriso S, Kempf R A et al.. Transient focal neurologic deficits complicating interleukin-2 therapy. Neurology. 1990; 40 154-155
43 Walker R W, Allen J C, Rosen G, Caparros B. Transient cerebral dysfunction secondary to high-dose methotrexate. J Clin Oncol. 1986; 4 1845-1850
44 Rubnitz J E, Relling M V, Harrison P L et al.. Transient encephalopathy following high-dose methotrexate treatment in childhood acute lymphoblastic leukemia. Leukemia. 1998; 12 1176-1181
45 Ay H, Buonanno F S, Schaefer P W et al.. Posterior leukoencephalopathy without severe hypertension: utility of diffusion-weighted MRI. Neurology. 1998; 51 1369-1376
46 Shin R K, Stern J W, Janss A J, Hunter J V, Liu G T. Reversible posterior leukoencephalopathy during the treatment of acute lymphoblastic leukemia. Neurology. 2001; 56 388-391
47 Sanchez-Carpintero R, Narbona J, Lopez de Mesa R, Arbizu J, Sierrasesumaga L. Transient posterior encephalopathy induced by chemotherapy in children. Pediatr Neurol. 2001; 24 145-148
48 Henderson R D, Rajah T, Nicol A J, Read S J. Posterior leukoencephalopathy following intrathecal chemotherapy with MRA-documented vasospasm. Neurology. 2003; 60 326-328
49 Smith G A, Damon L E, Rugo H S, Ries C A, Linker C A. High-dose cytarabine dose modification reduces the incidence of neurotoxicity in patients with renal insufficiency. J Clin Oncol. 1997; 15 833-839
50 Winkelman M D, Hines J D. Cerebellar degeneration caused by high-dose cytosine arabinoside: a clinicopathological study. Ann Neurol. 1983; 14 520-527
51 Brashear A, Siemers E. Focal dystonia after chemotherapy: a case series. J Neurooncol. 1997; 34 163-167
52 Anderson N R, Tandon D S. Ifosfamide extrapyramidal neurotoxicity. Cancer. 1991; 68 72-75
53 Resar L M, Phillips P C, Kastan M B et al.. Acute neurotoxicity after intrathecal cytosine arabinoside in two adolescents with acute lymphoblastic leukemia of B-cell type. Cancer. 1993; 71 117-123
54 Raney B, Tefft M, Heyn R et al.. Ascending myelitis after intensive chemotherapy and radiation therapy in children with cranial parameningeal sarcoma. Cancer. 1992; 69 1498-1506
55 McLean D R, Clink H M, Ernst P et al.. Myelopathy after intrathecal chemotherapy. Cancer. 1994; 73 3037-3040
56 Kleinschmidt-DeMasters B K, Yeh M. “Locked-in syndrome” after intrathecal cytosine arabinoside therapy for malignant immunoblastic lymphoma. Cancer. 1992; 70 2504-2507
57 Siegal T, Haim N. Cisplatin-induced peripheral neuropathy. Cancer. 1990; 66 1117-1123
58 Cavaletti G, Marzorati L, Bogliun G et al.. Cisplatin-induced peripheral neurotoxicity is dependent on total-dose intensity and single-dose intensity. Cancer. 1992; 69 203-207
59 Gill J S, Windebank A J. Cisplatin-induced apoptosis in rat dorsal root ganglion neurons is associated with attempted entry into the cell cycle. J Clin Invest. 1998; 101 2842-2850
60 Krarup-Hansen A, Rietz B, Krarup C et al.. Histology and platinum content of sensory ganglia and sural nerves in patients treated with cisplatin and carboplatin: an autopsy study. Neuropathol Appl Neurobiol. 1999; 25 29-40
61 Boogerd W, Huinink W W, Dalesio O, Hoppenbrouwers W J, van der Sande J. Cisplatin induced neuropathy: central, peripheral, and autonomic nerve involvement. J Neurooncol. 1990; 9 255-263
62 Heinzlef O, Lotz J P, Roullet E. Severe neuropathy after high dose carboplatin in three patients receiving multidrug chemotherapy. J Neurol Neurosurg Psychiatry. 1998; 64 667-669
63 Openshaw H, Slatkin N E, Stein A S, Hinton D R, Forman S J. Acute polyneuropathy after high dose cytosine arabinoside in patients with leukemia. Cancer. 1996; 78 1899-1905
64 Imrie K R, Couture F, Turner C C, Sutcliffe S B, Keating A. Peripheral neuropathy following high-dose etoposide and autologous bone marrow transplantation. Bone Marrow Transplant. 1994; 13 77-79
65 Stein M E, Drumea K, Yarnitsky D, Benny A, Tzuk-Shina T. A rare event of 5-fluorouracil-associated peripheral neuropathy. Am J Clin Oncol. 1998; 21 248-249
66 Patel S R, Forman A D, Benjamin R S. High-dose ifosfamide-induced exacerbation of peripheral neuropathy. J Natl Cancer Inst. 1994; 86 305-306
67 Koh S, Nelson M D, Kovanlikaya A, Chen L S. Anterior lumbosacral radiculopathy after intrathecal methotrexate treatment. Pediatr Neurol. 1999; 21 576-578
68 Gamelin E, Gamelin L, Bossi L, Quasthoff S. Clinical aspects and molecular basis of oxaliplatin neurotoxicity: current management and development of preventive measures. Semin Oncol. 2002; 29(Suppl 15) 21-33
69 Wilson R H, Lehky T, Thomas R R et al.. Acute oxaliplatin-induced peripheral nerve hyperexcitability. J Clin Oncol. 2002; 20 1767-1774
70 Taieb S, Trillet-Lenoir V, Rambaud L, Descos L, Freyer G. Lhermitte sign and urinary retention: atypical presentation of oxaliplatin neurotoxicity in four patients. Cancer. 2002; 94 2434-2440
71 Chaudhry V, Eisenberger M A, Sinibaldi V J et al.. A prospective study of suramin-induced peripheral neuropathy. Brain. 1996; 119 2039-2052
72 Soliven B, Dhand U K, Kobayashi K et al.. Evaluation of neuropathy in patients on suramin treatment. Muscle Nerve. 1997; 20 83-91
73 Cavaletti G, Bogliun G, Marzorati L et al.. Peripheral neurotoxicity of taxol in patients previously treated with cisplatin. Cancer. 1995; 75 1141-1150
74 Forsyth P S, Balmaceda C, Peterson K et al.. Prospective study of paclitaxel-induced peripheral neuropathy with quantitative sensory testing. J Neurooncol. 1997; 35 47-53
75 Hilkens P H, Verweij J, Stoter G et al.. Peripheral neurotoxicity induced by docetaxel. Neurology. 1996; 46 104-108
76 New P Z, Jackson C E, Rinaldi D, Burris H, Barohn R J. Peripheral neuropathy secondary to docetaxel (Taxotere). Neurology. 1996; 46 108-111
77 van den Bent M J, Hilkens P H, Sillevis Smitt P A et al.. Lhermitte's sign following chemotherapy with docetaxel. Neurology. 1998; 50 563-564
78 Chaudhry V, Rowinsky E K, Sartorius S E, Donehower R C, Cornblath D R. Peripheral neuropathy from Taxol and cisplatin combination chemotherapy: clinical and electrophysiological studies. Ann Neurol. 1994; 35 304-311
79 Freilich R J, Balmaceda C, Seidman A D, Rubin M, DeAngelis L M. Motor neuropathy due to docetaxel and paclitaxel. Neurology. 1996; 47 115-118
80 Chaudhry V, Chaudhry M, Crawford T O, Simmons-O'Brien E, Griffin J W. Toxic neuropathy in patients with pre-existing neuropathy. Neurology. 2003; 60 337-340
81 Berger T, Malayeri R, Doppelbauer A et al.. Neurological monitoring of neurotoxicity induced by paclitaxel/cisplatin chemotherapy. Eur J Cancer. 1997; 33 1393-1399
82 Molloy F M, Floeter M K, Syed N A et al.. Thalidomide neuropathy in patients treated for metastatic prostate cancer. Muscle Nerve. 2001; 24 1050-1057
83 Chaudhry V, Cornblath D R, Corse A et al.. Thalidomide-induced neuropathy. Neurology. 2002; 59 1872-1875
84 Casey E B, Jellife A M, Le Quesne P M, Millett Y L. Vincristine neuropathy: clinical and electrophysiological observations. Brain. 1973; 96 69-86
85 Graf W D, Chance P F, Lensch M W et al.. Severe vincristine neuropathy in Charcot-Marie-Tooth disease type 1A. Cancer. 1996; 77 1356-1362
86 Weintraub M, Adde M A, Venzon D J et al.. Severe atypical neuropathy associated with administration of hematopoietic colony-stimulating factors and vincristine. J Clin Oncol. 1996; 14 935-940
87 Pace A, Bove L, Nistico C et al.. Vinorelbine neurotoxicity: clinical and neurophysiological findings in 23 patients. J Neurol Neurosurg Psychiatry. 1996; 61 409-411
88 Apfel S C. Managing the neurotoxicity of paclitaxel and docetaxel with neurotrophic factors. Cancer Invest. 2000; 18 564-573
89 Cavaletti G, Zanna C. Current status and future prospects for the treatment of chemotherapy-induced peripheral neurotoxicity. Eur J Cancer. 2002; 38 1832-1837
90 Vahdat L, Papadopoulos K, Lange D et al.. Reduction of paclitaxel-induced peripheral neuropathy with glutamine. Clin Cancer Res. 2001; 7 1192-1197
91 Cascinu S, Catalano V, Cordella L et al.. Neuroprotective effect of reduced glutathione on oxaliplatin-based chemotherapy in advanced colorectal cancer. J Clin Oncol. 2002; 20 3478-3483

Edward J DropchoM.D.

Department of Neurology, Indiana University School of Medicine

541 Clinical Drive, CL 291

Indianapolis, IN 46202